// App-Quantinova.ai

AB0397 (2017) : ABATACEPT SHOWS BETTER SUSTAINABILITY THAN TNF INHIBITORS WHEN USED FOLLOWING INITIAL BIOLOGIC DMARD FAILURE IN THE TREATMENT OF RHEUMATOID ARTHRITIS: 8 YEARS OF REAL-WORLD OBSERVATIONS FROM THE RHUMADATA® CLINICAL DATABASE AND REGISTRY

Researchers

Presenter

  • D. Choquette

Principal Investigators

  • L. Bessette

  • E. Alemao

  • B. Haraoui

  • F. Massicotte

  • M. Mtibaa

  • E. Muratti

  • J.-P. Pelletier

  • R. Postema

  • J.-P. Raynauld

  • M.-A. Rmillard

  • D. Sauvageau

  • A. Turcotte

  • ?. Villeneuve

  • L. Coupal

Medical Centers

  • Rhumatology, Institut de recherche en rhumatologie de Montreal IRRM, Montreal, QC, Canada

  • Centre de l'Ostéoporose et de Rhumatologie de Québec, Québec, QC, Canada

  • Bristol Myers Squibb, Princeton, New Jersey, United States

  • Bristol-Myers Squibb, Montreal, QC, Canada

  • Bristol-Myers Squibb, Uxbridge, United Kingdom

Locations

  • Canada

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • Abatacept

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Amgen

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved